Trials / Terminated
TerminatedNCT05263492
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
A Multicenter, Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib in Combination With Pembrolizumab in Black Participants With Mismatch Repair-Proficient Recurrent Endometrial Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Virginia Commonwealth University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants
Detailed description
This study is a single-arm, open-label, multicenter phase 2 trial designed to prospectively evaluate the safety and efficacy of lenvatinib in combination with pembrolizumab for mismatch repair proficient recurrent endometrial cancer in Black patients (a population under-represented on 2 FDA registration trials).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | Lenvatinib once a day by mouth every day |
| DRUG | Pembrolizumab | Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks. |
Timeline
- Start date
- 2022-04-01
- Primary completion
- 2024-09-13
- Completion
- 2024-10-19
- First posted
- 2022-03-02
- Last updated
- 2025-10-02
- Results posted
- 2025-10-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05263492. Inclusion in this directory is not an endorsement.